

Title (en)  
COMBINATION THERAPY

Title (de)  
KOMBINATIONSTHERAPIE

Title (fr)  
POLYTHÉRAPIE

Publication  
**EP 3976100 A4 20230712 (EN)**

Application  
**EP 20812572 A 20200529**

Priority  
• US 201962855040 P 20190531  
• US 201962944698 P 20191206  
• IB 2020055128 W 20200529

Abstract (en)  
[origin: WO2020240502A2] The disclosure relates to methods and compositions for the treatment of a B-cell malignancy. Specifically, the disclosure relates to a B-cell malignancy medicament or composition, comprising: (a) an antibody-drug conjugate (ADC) comprising an antibody or antigen-binding fragment thereof that binds to B-cell maturation antigen (BCMA), conjugated to a nucleic acid cross-linking agent; and (b) a proteasome inhibitor.

IPC 8 full level  
**C07K 16/28** (2006.01); **A61K 31/407** (2006.01); **A61K 31/427** (2006.01); **A61K 31/69** (2006.01); **A61K 39/00** (2006.01); **A61K 39/395** (2006.01); **A61K 39/44** (2006.01); **A61K 47/68** (2017.01); **A61P 35/00** (2006.01); **A61P 35/02** (2006.01)

CPC (source: EP IL KR US)  
**A61K 31/407** (2013.01 - EP IL US); **A61K 31/427** (2013.01 - EP IL US); **A61K 31/69** (2013.01 - EP IL KR US); **A61K 39/39558** (2013.01 - EP IL); **A61K 45/06** (2013.01 - KR); **A61K 47/6803** (2017.08 - IL KR US); **A61K 47/68035** (2023.08 - EP); **A61K 47/6849** (2017.08 - EP IL KR US); **A61K 47/6889** (2017.08 - EP IL KR US); **A61P 35/00** (2018.01 - EP); **A61P 35/02** (2018.01 - EP IL KR); **C07K 16/2878** (2013.01 - EP IL KR US); **A61K 2039/505** (2013.01 - EP); **A61K 2300/00** (2013.01 - IL KR); **C07K 2317/73** (2013.01 - EP IL KR US); **C07K 2317/92** (2013.01 - EP IL KR US)

C-Set (source: EP)  
1. **A61K 39/39558 + A61K 2300/00**  
2. **A61K 31/69 + A61K 2300/00**  
3. **A61K 31/407 + A61K 2300/00**  
4. **A61K 31/427 + A61K 2300/00**

Citation (search report)  
• [A] WO 2019053611 A1 20190321 - GLAXOSMITHKLINE IP DEV LTD [GB]  
• [Y] WO 2019025983 A1 20190207 - MEDIMMUNE LLC [US]  
• [XY] WO 2014089335 A2 20140612 - AMGEN INC [US]  
• [XY] WO 2018201051 A1 20181101 - NOVARTIS AG [CH], et al  
• [Y] WO 2017143069 A1 20170824 - SEATTLE GENETICS INC [US]  
• [A] WO 2017214456 A1 20171214 - ABBVIE INC [US]  
• [Y] KINNEER KRISTA ET AL: "Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells", LEUKEMIA, NATURE PUBLISHING GROUP UK, LONDON, vol. 33, no. 3, 12 October 2018 (2018-10-12), pages 766 - 771, XP036719759, ISSN: 0887-6924, [retrieved on 20181012], DOI: 10.1038/S41375-018-0278-7

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)  
BA ME

Designated validation state (EPC)  
MA TN

DOCDB simple family (publication)  
**WO 2020240502 A2 20201203; WO 2020240502 A3 20210715**; AU 2020284723 A1 20220127; BR 112021023748 A2 20220104; CA 3140762 A1 20201203; CL 2021003144 A1 20220909; CN 114555114 A 20220527; CO 2021017477 A2 20220520; CR 20210685 A 20220513; EC SP21091482 A 20220225; EP 3976100 A2 20220406; EP 3976100 A4 20230712; IL 288237 A 20220101; JP 2022534969 A 20220804; KR 20220016188 A 20220208; MA 56057 A 20220406; MX 2021014553 A 20220519; SG 11202113008Y A 20211230; US 2022218835 A1 20220714

DOCDB simple family (application)  
**IB 2020055128 W 20200529**; AU 2020284723 A 20200529; BR 112021023748 A 20200529; CA 3140762 A 20200529; CL 2021003144 A 20211126; CN 202080039475 A 20200529; CO 2021017477 A 20211220; CR 20210685 A 20200529; EC DI202191482 A 20211217; EP 20812572 A 20200529; IL 28823721 A 20211118; JP 2021570788 A 20200529; KR 20217043057 A 20200529; MA 56057 A 20200529; MX 2021014553 A 20200529; SG 11202113008Y A 20200529; US 202017595671 A 20200529